| [1] |
Collins AJ, Foley RN, Chavers B, et al. US renal data system 2013 annual data report [J]. Am J Kidney Dis, 2014, 63(Suppl 1): e1-e478.
|
| [2] |
Cheung AK, Sarnak MJ, Yan G, et al. Cardiac diseases in maintenance hemodialysis patients: results of the HEMO study [J]. Kidney Int, 2004, 65(6): 2380-2389.
|
| [3] |
Wanner C, Krane V, März W, et al. Atorvastatin in patients with type 2 diabetes mellitus undergoing hemodialysis [J]. N Engl J Med, 2005, 353(3): 238-248.
|
| [4] |
Rao GA, Mann JR, Shoaibi A, et al. Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death [J]. Ann Fam Med, 2014, 12(2): 121-127.
|
| [5] |
Mortensen EM, Halm EA, Pugh MJ, et al. Association of azithromycin with mortality and cardiovascular events among older patients hospitalized with pneumonia [J]. JAMA, 2014, 311(21): 2199-2208.
|
| [6] |
Pun PH, Horton JR, Middleton JP. Dialysate calcium concentration and the risk of sudden cardiac arrest in hemodialysis patients [J]. Clin J Am Soc Nephrol, 2013, 8(5): 797-803.
|
| [7] |
Huang YC, Huang JC, Chen SC, et al. Lethal cardiac arrhythmia during central venous catheterization in a uremic patient: a case report and review of the literature [J]. Hemodial Int, 2013, 17(4): 644-648.
|
| [8] |
Verde E, Pérez de Prado A, López-Gómez JM, et al. Asymptomatic intradialytic supraventricular arrhythmias and adverse outcomes in patients on hemodialysis [J]. Clin J Am Soc Nephrol, 2016, 11(12): 2210-2217.
|
| [9] |
Zebe H. Atrial fibrillation in dialysis patients [J]. Nephrol Dial Transplant, 2000, 15(6): 765-768.
|
| [10] |
Vázquez E, Sánchez-Perales C, Borrego F, et al. Influence of atrial fibrillation on the morbido-mortality of patients on hemodialysis [J]. Am Heart J, 2000, 140(6): 886-890.
|
| [11] |
Genovesi S, Vincenti A, Rossi E, et al. Atrial fibrillation andmorbidity and mortality in a cohort of long-term hemodialysis patients [J]. Am J Kidney Dis, 2008, 51(2): 255-262.
|
| [12] |
Makar MS, Pun PH. Sudden cardiac death among hemodialysis patients [J]. Am J Kidney Dis, 2017, 69(5): 684-695.
|
| [13] |
Karaboyas A, Zee J, Brunelli SM, et al. Dialysate potassium, serum potassium, mortality, and arrhythmia events in hemodialysis: results from the dialysis outcomes and practice patterns study (DOPPS) [J]. Am J Kidney Dis, 2017, 69(2): 266-277.
|
| [14] |
Ozportakal H, Ozkok A, Alkan O, et al. Hemodialysis-induced repolarization abnormalities on ECG are influenced by serum calcium levels and ultrafiltration volumes [J]. Int Urol Nephrol, 2017, 49(3): 509-515.
|
| [15] |
Priori SG, Blomström-Lundqvist C, Mazzanti A, et al. 2015 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death [J]. Euro Heart J, 2015, 36(41): 2793-2867.
|
| [16] |
Wheeler DC, London GM, Parfrey PS, et al. Effects of cinacalcet on atherosclerotic and nonatherosclerotic cardiovascular events in patients receiving hemodialysis: the evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial [J]. J Am Heart Assoc, 2014, 3(6): e001363.
|
| [17] |
《心律失常紧急处理专家共识》专家工作组. 心律失常紧急处理专家共识[J]. 中华心血管病杂志，2013, 41(5)：363-376.
|
| [18] |
陈香美. 临床诊疗指南肾脏病分册[M]. 北京：人民卫生出版社，2011：266.
|
| [19] |
National Kidney Foundation. K/DOQI clinical practice guidelines for cardiovascular disease in dialysis patients [J]. Am J Kidney Dis, 2005, 45(Suppl 3): S1-S154.
|
| [20] |
Kontos MC, Diercks DB, Ho PM, et al. Treatment and outcomes in patients with myocardial infarction treated with acute beta-blocker therapy: results from the American College of Cardiology′s NCDR [J]. Am Heart J, 2011, 161(5): 864-870.
|
| [21] |
Kusumoto FM, Bailey KR, Chaouki AS, et al. 2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death [J]. J Am Coll Cardiol, 2017, Epub ahead of print.
|
| [22] |
Alberte C, Zipes DP. Use of nonantiarrhythmic drugs for prevention of sudden cardiac death [J]. J Cardiovasc Electrophysiol, 2003, 14(Suppl 9): S87-S95.
|
| [23] |
Pitt B, RemmeW, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction [J]. N Engl J Med, 2003, 348(14): 1309-1321.
|